Using precision medicine
to improve patient outcomes
PrismRA® introduces precision medicine to the treatment of rheumatoid arthritis for the first time, providing objective, science-based guidance for rheumatoid arthritis (RA) therapy selection. The test leverages RNA expression data to identify patients who are unlikely to adequately respond to TNF inhibitor (TNFi) therapies, a targeted therapy commonly used to treat RA, based on their distinct molecular signatures.
The PrismRA test analyzes 23 biological features, including RNA expression data, demographic variables, and disease-associated clinical metrics, that are discriminatory between the molecular signatures of those who respond or do not respond adequately to TNFi therapies.
Identifying molecular signatures indicative of inadequate response
A molecular signature combines a set of biological features to capture an individual’s genetic makeup and disease behavior. These features include RNA, proteins, and other features that reflect a patient’s distinctive disease biology.
Targeted therapies, like TNFi therapies, target specific disease related proteins. Because a disease affects each patient differently, a targeted therapy may work for some patients but not others. An RA patient may fail to have an adequate response to a TNFi therapy if his or her molecular signature is not sufficiently driven by the TNF-ɑ pathway.
PrismRA combines RNA expression data, demographic variables, and disease-associated clinical metrics to increase a molecular signature’s power to predict if a patient will respond inadequately to a TNFi therapy.
Deciphering molecular signatures can predict how patients will respond to different therapies
Incorporating PrismRA into clinical management of patients with RA can improve patient quality of life and save time by enabling physicians to prescribe a more effective therapy sooner.1,2